Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative therapies for serious muscle diseases. Founded in 2017, Dyne has quickly established itself in the biopharmaceutical industry, particularly in the realm of gene therapy and muscle-targeted drug development. The company’s core offerings include its proprietary FORCE™ platform, which enables the creation of targeted therapies that address the underlying causes of muscle disorders. This unique approach positions Dyne Therapeutics as a leader in the market, with a commitment to transforming the lives of patients suffering from debilitating conditions. With significant advancements in its research and development pipeline, Dyne Therapeutics continues to make notable strides, solidifying its reputation as a key player in the biotechnology sector.
DitchCarbon Score
How does Dyne Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dyne Therapeutics, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dyne Therapeutics, Inc.'s reported carbon emissions
Dyne Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Consequently, there are no documented Scope 1, 2, or 3 emissions or any reduction targets or achievements available at this time. The company has not established any publicly available climate commitments or initiatives, nor does it inherit emissions data from a parent organisation. As such, Dyne Therapeutics appears to be in the early stages of developing its climate strategy and emissions reporting framework. In the context of the biotechnology industry, it is increasingly important for companies to set measurable climate targets and engage in sustainability practices to align with global climate goals. As Dyne Therapeutics progresses, it may consider adopting industry-standard frameworks such as the Science Based Targets initiative (SBTi) to enhance its climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dyne Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
